Actemra and Leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Leukoencephalopathy is reported as a side effect among people who take Actemra (tocilizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Bactrim, and have Hyperlipidaemia.

The phase IV clinical study analyzes which people have Leukoencephalopathy when taking Actemra. It is created by eHealthMe based on reports of 102,551 people who have side effects when taking Actemra from the FDA, and is updated regularly.

What is Actemra?

Actemra has active ingredients of tocilizumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 102,759 Actemra users. Check the latest studies of Actemra.

What is Leukoencephalopathy?

Leukoencephalopathy (disease of the white matter in the brain) is found to be associated with 386 drugs and 626 conditions by eHealthMe. Check the latest studies of Leukoencephalopathy.

On Jul, 15, 2026

102,551 people reported to have side effects when taking Actemra.
Among them, 23 people (0.02%) have Leukoencephalopathy.

Could Actemra cause Leukoencephalopathy?

Among these 23 people:

How long have people been on Actemra when they have Leukoencephalopathy? *

What is the gender of people who have Leukoencephalopathy when taking Actemra? *

female: 73.91 %
male: 26.09 %

What is the age of people who have Leukoencephalopathy when taking Actemra? *

What are other drugs people take besides Actemra? *

What are other side effects people have besides Leukoencephalopathy? *

Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 4 people, 17.39%
Endocarditis Staphylococcal (an inflammation of the inner layer of the heart by staphylococcal bacterial infection): 3 people, 13.04%
Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 3 people, 13.04%
Pancreatitis (inflammation of pancreas): 3 people, 13.04%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 3 people, 13.04%
Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 3 people, 13.04%
Encephalitis Autoimmune (autoimmune origin disturbances of consciousness and pyramidal signs, inflammation of the brain): 3 people, 13.04%
Thrombocytopenia (decrease of platelets in blood): 2 people, 8.70%
Aneurysm (enlargement of an artery caused by a weakening of the artery wall): 2 people, 8.70%
Bedridden: 2 people, 8.70%

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 13.04%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 8.70%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 2 people, 8.70%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 8.70%
Gait Disturbance: 1 person, 4.35%
Castleman's Disease (a disease of lymph nodes and related tissues): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Actemra and have Leukoencephalopathy?

- Check whether Leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Actemra:

Actemra (102,759 reports)

Browse all side effects of Actemra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Leukoencephalopathy:

Leukoencephalopathy (386 drugs)

Browse all the conditions that are associated with Leukoencephalopathy:

Leukoencephalopathy (626 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tocilizumab (the active ingredients of Actemra) and Actemra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.